Innovation. Identification. Integrity.
Real-Time Diagnostics for Modern Infectious Disease Management
SARS-CoV-2 Delta Variant Detected by Integrity Laboratories FDA EUA approved Assay
9 Viral Variants | 3 Viral Load Indicators | 1 RT-PCR Test
| NIH GenBank® ID | GISAID Name |
|---|---|
| MT007544.1 | Australia/VIC01/2020 |
| MN908947.3 | Wuhan-Hu-1 |
| LC528232.1 | Japan/Hu_DP_Kng_19-020/2020 |
| MT106054.1 | USA/TX1/2020 |
| MT188340 | USA/MN2-MDH2/2020 |
| MT118835 | USA/CA9/2020 |
| EPI_ISL_710528 | England/205041766/2020 |
| EPI_ISL_601443 | England/MILK-9E05B3/2020 |
Leadership Thoughts
CDC reports transmission of drug-resistant Candida auris with threat level - urgent
Candida auris is an emerging multi-drug resistant, highly transmissible yeast (a type of fungus) affecting especially severely ill patients with...
Customer Care: The Patient Always Matters
One of the greatest misconceptions about the field of diagnostics is that as scientists, we care more about results than we do about customer and patient
Thank You for Honoring Us with a Pinnacle Business Award
2020 was a year for significant change – for patients, for hospitals, for businesses, and for daily life. The many obstacles we have faced as atry
The New Standard In High-Performance Clinical Diagnostics
We are the leading biotechnology firm committed to antimicrobial stewardship through high-complexity clinical diagnostics.
We improve healthcare for all by enabling the expedited delivery of targeted antimicrobial therapies the first time, every time.
We partner with the most trusted providers, healthcare systems, and insurance networks to deliver best-in-class technologies that lower costs and improve outcomes.
Next-Generation Infection Management for Patients Across Any Site of Care
- Advanced Diagnostic Reporting in Less Than 24 Hours
- Precision Antibiotic Resistance Markers
- Therapy Guidance Based Upon Objective Data and Analytics
- Lowering Costs, Improving Outcomes, Healthier Patients
Introducing A Novel Approach To Antimicrobial Stewardship
The intercept PCR™ molecular diagnostics platform enables providers to order same-day and next-day diagnostic data on complicated patient conditions through non-invasive methods. intercept PCR™ also excels as a simplified integration solution that is complimentary, not competitive, to existing laboratory arrangements across any clinical setting.
High Speed
High Fidelity
STAT and Next Day results report across all testing modalities. Specificity of molecular diagnostics testing at greater than 99%. Ability to differentiate specimens which are polymicrobial compared to traditional culture.
Integrated Data
Actionable Analytics
Intercept PCR™ is the dynamic data engine behind the molecular diagnostics platform. Providers and systems gain access to a unique portal form which they can access real-world data and quantify impacts of enhanced antibiotic prescribing patterns.
Lowering Costs
Improving Outcomes
Antimicrobial stewardship is a strategic approach to antibiotic prescribing. This practice is evidence-based and paramount to delivering value-based therapy. Real-time and near-time diagnostic insights help guide earlier and more effective therapeutic intervention.
